Last reviewed · How we verify
CCRT with weekly docetaxel & cisplatin
Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death.
Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death. Used for Non-small cell lung cancer, Prostate cancer, Breast cancer.
At a glance
| Generic name | CCRT with weekly docetaxel & cisplatin |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Taxane and platinum-based chemotherapeutic agents |
| Target | Microtubules and DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Docetaxel binds to tubulin, preventing microtubule polymerization, and cisplatin forms platinum-DNA adducts, inhibiting DNA replication and transcription.
Approved indications
- Non-small cell lung cancer
- Prostate cancer
- Breast cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Diarrhea
Key clinical trials
- Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer (PHASE2, PHASE3)
- A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma (PHASE3)
- Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer (PHASE2)
- Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer (NA)
- Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
- A Study of Tongue Conservation Surgery for Oral Tongue Cancer (PHASE2)
- Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer (PHASE3)
- Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CCRT with weekly docetaxel & cisplatin CI brief — competitive landscape report
- CCRT with weekly docetaxel & cisplatin updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI